← United States · All US Insider Profiles
US INSIDER PROFILE · NON-SCORING RESEARCH
Zanganeh Mahkam
Chief Executive Officer | Officer
Identity: SEC reporting-owner CIK · Reporting-owner CIK: 0001507650
Purchase history
- Companies traded
- 1
- Purchases · 12M
- 3
- Purchases · 24M
- 4
- Average purchase
- $14.5M
- Median purchase
- $3.7M
- Gross purchase value
- $57.9M
Companies: Summit Therapeutics Inc.
4 SEC accession(s) · 0 joint-owner event(s). Values are reported Form 4 transaction values in USD.
Qualifying purchase disclosures
| Published | Company | Ticker | Role | Reported value | SEC source |
|---|---|---|---|---|---|
| 2026-06-12 | Summit Therapeutics Inc. | SMMT | Chief Executive Officer | Officer | $50.0M | Open filing |
| 2026-06-04 | Summit Therapeutics Inc. | SMMT | Chief Executive Officer | Officer | $1.5M | Open filing |
| 2025-10-23 | Summit Therapeutics Inc. | SMMT | Chief Executive Officer | Officer | $500.0K | Open filing |
| 2025-09-11 | Summit Therapeutics Inc. | SMMT | Chief Executive Officer | Officer | $6.0M | Open filing |
Post-purchase outcomes
Excess return = stock return − S&P 500 ETF (SPY adjusted close) return. Returns start on the first shared trading session on or after publication.
| Period | Completed events | Price coverage | Hit rate | Median excess return | Average excess return | Worst excess return |
|---|---|---|---|---|---|---|
| 5D | 4Small Sample | 100.0% (4/4) | 50.0% (2/4) | -0.2% | -1.8% | -9.3% |
| 20D | 4Small Sample | 100.0% (4/4) | 75.0% (3/4) | +8.3% | +6.7% | -9.4% |
| 60D | 4Small Sample | 100.0% (4/4) | 25.0% (1/4) | -8.0% | -1.6% | -12.5% |
| 120D | 2Small Sample | 100.0% (2/2) | 50.0% (1/2) | +2.0% | +2.0% | -23.9% |
Research patterns
- First purchase in 12M
- 0/3
- Large purchase ≥ $100k
- 4/4
- Cluster buying · 15D
- 4/4
- Buying the dip
- 4/4
Routine / opportunistic: Not classifiable. These labels never affect the score or ranking.
Small samples remain visible but are not scored. This research enrichment never affects US-v1.1.